KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell ...

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

As a risk factor for future serious health conditions, the early prevention, detection and management of type 2 diabetes are ...

According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.

Biogen plans to start a Phase III trial for felzartamab as a treatment for antibody-mediated rejection, and two other ...

Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and ...

At CPHI Europe, an expert discussed the promise of gummies as a drug delivery system and their unique manufacturing ...

Arda Therapeutics has secured $43m in Series A financing led by Andreessen Horowitz to develop targeted cell depletion ...

Patient recruitment is a critical yet challenging phase in clinical trials. EMIS has been lauded for its significant ...